We are live on ! Find out more
BCLSI

Bain Capital Life Sciences Investors Portfolio holdings

AUM $1.11B
1-Year Est. Return 171.34%
This Fund
S&P 500
This Quarter Est. Return
+51.43%
1 Year Est. Return
+171.34%
3 Year Est. Return
+643.23%
5 Year Est. Return
+451.99%
10 Year Est. Return
–
AUM
$1.24B
AUM Growth
+$201M
Cap. Flow
-$41.4M
Cap. Flow %
-3.33%
Top 10 Hldgs %
81.83%
Holding
29
New
2
Increased
3
Reduced
11
Closed
3

Top Buys

Rank Stock Value
1
KYTX icon
Kyverna Therapeutics
KYTX
+$88.3M
2
DNTH icon
Dianthus Therapeutics
DNTH
+$65M
3
SLDB icon
Solid Biosciences
SLDB
+$8.46M
4
ANNX icon
Annexon
ANNX
+$3.33M
5
SVRA icon
Savara
SVRA
+$1.61M

Top Sells

Rank Stock Value
1
NUVL
Nuvalent
NUVL
+$70M
2
RVMD icon
Revolution Medicines
RVMD
+$31.9M
3
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$30.1M
4
NTRA icon
Natera
NTRA
+$25.1M
5
PHVS icon
Pharvaris
PHVS
+$16M

Sector Composition

Rank Sector Weight
1 Healthcare 98.9%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NAMSW icon
26
NewAmsterdam Pharma Warrant
NAMSW
$78.2M
$1.1M 0.09%
100,000
– –
NTRA icon
27
Natera
NTRA
$45.5B
– –
-400,197
Closed -$25.1M
RVMD icon
28
Revolution Medicines
RVMD
$44B
– –
-1,112,396
Closed -$31.9M
TSVT
29
DELISTED
2seventy bio
TSVT
– –
-1,331,801
Closed -$5.69M
1
2

Similar funds

JTWM
Jackson Thornton Wealth Management Montgomery, Alabama $1.11B AUM 22.53% 1-Year Est. Return
HH
Hilltop Holdings Dallas, Texas $1.11B AUM 24.7% 1-Year Est. Return
RIM
Rockbridge Investment Management Syracuse, New York $1.11B AUM 13.62% 1-Year Est. Return
YL
YCG LLC Austin, Texas $1.1B AUM 4.87% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
AIM
Advyzon Investment Management Lisle, Illinois $1.12B AUM 22.08% 1-Year Est. Return
MTCM
Mint Tower Capital Management Amsterdam, Netherlands $1.12B AUM 18.84% 1-Year Est. Return
CNC
Canandaigua National Corp Canandaigua, New York $1.12B AUM

Bain Capital Life Sciences Investors's Q1 2024 Portfolio in Review

As of Q1 2024, Bain Capital Life Sciences Investors held 29 positions worth $1.24B, up 19% from $1.04B the previous quarter. Its ten largest holdings account for 82% of the portfolio.

Bain Capital Life Sciences Investors withdrew a net $41.4M in Q1 2024, closing 3 positions and reducing 11 holdings. Its most notable exit was Revolution Medicines, an estimated $31.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier.

Against the trend, Bain Capital Life Sciences Investors opened a new position in Kyverna Therapeutics worth $78.6M.

  • Bain Capital Life Sciences Investors's largest Q1 2024 buy was Kyverna Therapeutics: 3,163,868 shares worth $78.6M.
  • Bain Capital Life Sciences Investors added most to Solid Biosciences in Q1 2024, an estimated $8.46M increase.
  • Bain Capital Life Sciences Investors's biggest Q1 2024 reduction was Nuvalent, cutting an estimated $70M.
  • Bain Capital Life Sciences Investors fully exited Revolution Medicines in Q1 2024, selling an estimated $31.9M.
  • Bain Capital Life Sciences Investors's ten largest holdings make up 82% of its $1.24B portfolio in Q1 2024.
  • Bain Capital Life Sciences Investors opened 2 new positions and closed 3 in Q1 2024.
  • Bain Capital Life Sciences Investors's portfolio value rose 19% quarter-over-quarter to $1.24B.

Based on Bain Capital Life Sciences Investors's 13F filing for Q1 2024, filed 15 May 2024.